Expired activity
Please go to the PowerPak homepage and select a course.

Pharmacist Perspectives: Exploring the Evolving Role of BTK Inhibitors in CLL

This educational activity is presented by Creative Educational Concepts, Inc., and is supported by an independent educational grant from AstraZeneca.

This CPE activity is based on the slides and lectures presented by faculty during a live, virtual symposium for the Hematology/Oncology Pharmacy Association’s (HOPA) 16th Annual Conference on Friday, March 13, 2020.


Kathy Hogan Edwards, PharmD, BCPS, BCOP
Clinical Pharmacy Specialist Blood and Marrow Transplantation
Hollings Cancer Center
Affiliate Associate Professor, College of Pharmacy
Medical University of South Carolina
Charleston, South Carolina

Emily K. Dotson, PharmD, BCOP
Clinical Pharmacist Specialist–Hematology Lead
Hematology Inpatient/Outpatient
The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
The Ohio State University
Columbus, Ohio

Needs Statement

Participants will gain exposure to emerging clinical and scientific advances in the treatment of chronic lymphocytic leukemia (CLL) with BTK inhibitors (BTKis), including novel pharmacologic targets within the B-cell receptor (BCR) pathway, and the latest, top-line safety and efficacy trial data for BTK inhibitors in both treatment-naïve (TN) and relapsed/refractory (R/R) CLL. Prominent mechanisms of BTK inhibitor resistance and adaptive strategies used to prevent and/or mitigate the development of resistance also will be explored. Using a case-based approach, there is discussion focused on common clinical challenges, anticipation and management of adverse events, promotion of patient adherence, and optimization of outcomes for patients with CLL.

Target Audience

This activity is designed to meet the educational needs of oncology pharmacists, pharmacy directors, and pharmacy residents.


At the conclusion of this enduring activity, participants will be able to:

  1. Describe the role of the B-cell receptor (BCR) pathway in the pathophysiology of B-cell malignancies and delineate the mechanistic rationale for targeting the BCR pathway in chronic lymphocytic leukemia (CLL) management.
  2. Examine the safety and efficacy profiles of both currently available and emerging BTK inhibitors (BTKis) and appraise their respective therapeutic roles in treatment-naïve (TN) and relapsed/refractory (R/R) CLL.
  3. Explore prominent resistance mechanisms seen with BTK inhibitors and discuss established mitigation strategies.
  4. Using a case-based approach, identify common challenges clinicians face when using BTK inhibitors, assess adaptive strategies oncology pharmacists can employ to anticipate and manage adverse effects, improve adherence to therapy, and ultimately, optimize outcomes for patients with CLL.


In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This application-based activity is approved for 1.0 contact hours (0.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-014-H01-P).

Creative Educational Concepts, Inc. certifies this activity for 1.0 hours of participation.

Faculty Disclosure

Planner and Faculty Disclosures
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Vanessa Carranza, PharmD—has no relevant financial relationships to disclose in relation to the content of this activity.

Kathy Hogan Edwards, PharmD, BCPS, BCOP—has disclosed that she is a consultant for Genzyme Corporation.

Emily K. Dotson, PharmD, BCOP—has disclosed that she is a consultant for AstraZeneca.

Content Reviewer
Bryan C. Taylor, PharmDhas no relevant financial relationships to disclose in relation to the content of this activity.

Activity Instructions

Media: Internet Web Activity (PowerPoint slides and audio)


To receive a statement of credit, you must:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Review the full content of the activity and reflect upon its teaching.
  3. Complete the questions and evaluation at the end of the activity.
  4. You must have a passing score of 80% on the post-test. You will have two (2) opportunities to complete the post-test.